Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CMet/AXL Selective Inhibitor by BioSeedin for Gastric Cancer: Likelihood of Approval
CMet/AXL Selective Inhibitor is under clinical development by BioSeedin and currently in Phase I for Gastric Cancer. According to GlobalData,...